GiveBetter x New York City

Newark Community Street Team

Community violence intervention, trauma recovery and overdose response

Research time: ~6 min on GPT-6 Astra Light + ~2 min on GPT-6.1 Sol
  • Research — reviewed programs, finances and impact evidence.
  • Source audit — checked claims, assumptions and calculations.
  • Modeling — estimated costs, QALYs and uncertainty.

Updated: 2026-10-08

Donate

Summary

What do they do? Newark Community Street Team responds to high-risk conflicts, supports injured people and survivors, and provides trauma care and overdose response. Its ordinary recipient portfolio also includes school safety, crisis response, community organizing and public-safety partnerships. The conditional estimate prices several central clinical pathways against the full recipient cost, while leaving wider neighborhood, educational and institutional effects unpriced.

Why we’re interested in this organization:

  • Current original accounts and a detailed 2025 evaluation identify a substantial local service portfolio.

  • The model includes prevention of new violent injury, trauma recovery and unique-person overdose survival rather than equating contacts with lives saved.

  • The latest audit documents corrective actions and the separate fiscal-sponsorship perimeter.

Our main reservations:

  • The local evaluation explicitly lacks a control group and cannot establish a causal reduction in violence.

  • Return narratives repeat some counts across years and mix clients, participants and cumulative totals, so effective annual reach remains uncertain.

  • Public contracts, emergency responders and other providers can substitute for donations; long-term neighborhood effects may be much larger or smaller than the priced component.

What do you get for your dollar? $5.6M per DALY in New York City. DALY is our one-year comparison unit. QALY-based health gains and income-welfare equivalents retain their original assumptions; they are not measured clinical DALYs. Partial clinical reference; household resources assessed unknown.

Distinct high-risk mediation opportunities and current hospital enrollments translated to net new violent injuries prevented. Existing-survivor clinical episodes translated to incremental finite trauma recovery. Naloxone reversals deduplicated to people with incremental timely rescue and finite survival.

1. What do they do?

NCST’s current programs combine outreach and high-risk intervention with hospital-based violence intervention, victim services, a trauma recovery center, school Safe Passage and crisis response. The 2024 original return also identifies an active overdose response team. These are linked parts of a local safety system, not independent beneficiary lists. The estimate covers the most directly defensible material health pathways across that system; it is not merely a price for naloxone and it is not a full social-return estimate.

2. Monitoring and information sharing

The November 2025 UCLA evaluation uses qualitative work through July 2025 and quantitative data from January 2022 to March 2024. It explicitly states that no control group permits causal identification. Positive contemporaneous correlations between interventions and crime principally document reactive deployment, not crimes prevented; nearby stronger causal language is not supported by that design. The 2024 return reports 119 mediations, 137 hospital-program consents, 265 trauma-program participants and 30 naloxone reversals. Some counts repeat older narratives or conflict with cumulative client descriptions. The model therefore applies explicit current-annual and overlap adjustments, and does not sum 15,185 event participants as unique beneficiaries.

3. Qualitative assessment

The 2026 EAST review conditionally supports hospital violence programs, but rates its heterogeneous evidence low quality. The odds ratio is transferred through an assumed baseline injury risk and a further local-effect attenuation, not called an NCST trial. The local evaluation supports trust, immediate response and survivor-service mechanisms. Overdose response can be valuable, but arriving before EMS is not equivalent to preventing a death; unique people, otherwise-timely rescue and competing mortality are modeled separately. School safety, institutional legitimacy, housing assistance and broader community spillovers could be important and remain outside the modeled health numerator; their recipient costs remain in the full-cost denominator.

Household assistance, compensation, care payments and work resources require targeted assessment; they are unknown, not zero.

4. What do you get for your dollar?

Signed household resources are assessed unknown and potentially material. The retained clinical reference is about $5.6M per DALY, with 1.151635742126023 MSA QALYs at $6,443,440 of full annual recipient resources. This is not a complete combined valuation, zero-income finding or measured 90% health share. All ten original worlds remain unchanged.

The current NCST program page describes access up to $200 hardship assistance, free legal support, victim compensation applications, employment referrals and free Trauma Recovery Center services. The ceiling is not average assistance paid; applications and referrals are not compensation or job wins. A numerical bridge needs deduplicated funding-responsive households, actual retained payments and private-payment displacement against existing free services or otherwise forgone treatment, net household baseline and finite timing. Taxes, benefits withdrawn and full travel, time, administration and work costs must be included independently of clinical response. Positive overlap applies only to gains. Public/provider resources and financing transfers are separate incidence, not household cash; no retail treatment value, gross wages or ordinary survivor earnings is credited. Broader resource effects remain unquantified, not absent.

FY2024 original audited expense is $6,286,421: Form 990 Part IX $6,263,321 plus $23,100 donated use of premises (rent). No separately netted event or inventory costs were reported. Its expense total includes a $157,019 recovery of previously uncollectible receivables; the central forward resource cost adds that credit back, giving $6,443,440, with the audited-total alternative shown separately. FY2023 audited expense is $8,131,996. FY2022 gross expense is $6,362,857 ($6,333,008 plus $29,849 donated services), but is not comparable because it included a CBPSC fiscal-sponsorship perimeter that phased out in early 2023. No synthetic three-year mean is used. Full recipient cost includes administration and unpriced programs; external clinical and emergency resources receive a separate sensitivity.

Model, assumptions and sensitivity

Full recipient annual forward resource cost, including donated services and unpriced programs. Partial multi-pathway clinical denominator; not all portfolio value.

Newark is in Essex County within the official 22-county NYC MSA. g=0.98 is a direct-beneficiary retention prior, not a headquarters-based share of national CBPSC work.

F(r,T)=(1-exp(-(r+ln(1+d))*T))/(r+ln(1+d)). V=oV*[M*fM*pM+H*fH*l*(r0-OR*r0/(1-r0+OR*r0))]. QV=V*[(1-z)*ui*F(ri,Ti)+z*ud*F(md,Td)]. QT=T*fT*pT*uT*F(rT,TT). QR=R*oR*tR*deltaR*uR*F(mR,TR). Q_all=a*b*(QV+QT+QR-h); Q_NYC=g*Q_all; price=10*C/Q_NYC if positive, else null. V counts unique newly prevented violent injuries, QT existing-survivor recovery, QR unique overdose survival. Effects are valued at onset; one-year delay multiplies Q by 1/1.03.

C
6443440 USD annual whole-recipient forward resource cost (observed). Audited expense 6,286,421 plus reversal of the 157,019 prior receivable-recovery credit; this is a forward-cost normalization, not extra audited spending. [audit2024] [d2024]
M
119 reported mediations in 2024 (observed). Part III reported 119; not the evaluation’s differently defined and much larger logged HRI event count. [return2024]
fM
0.6 fraction representing distinct current-year effective mediation opportunities (judgment). 60% prior handles repeat conflicts, unique opportunities and current capacity; no claim of audited reach. [evaluation]
pM
0.03 net violent injury probability reduction per effective mediation (judgment). 3 percentage points net difference for one-year mediation opportunity, not 3% of all city crime. [evaluation]
H
137 reported hospital-program consents (observed). Part III says 137 consents; the same number occurs in an older return narrative, so treat temporal accuracy as uncertain. [return2024]
fH
0.8 fraction representing effective current annual hospital enrollments (judgment). 80% current-effective fraction; original reported consents are not verified unique current completions. [evaluation]
r0
0.1 two-year violent reinjury risk without HVIP (judgment). 10% two-year untreated reinjury risk is a local prior, not supplied by the external pooled odds ratio. [hvip2026]
OR
0.6 odds ratio of violent reinjury, external review (observed). 0.60 (95% CI 0.38–0.94), 10-study meta-analysis; low quality and heterogeneous, not NCST causal evidence. [hvip2026]
l
0.5 local transfer fraction of external risk difference (judgment). Half the external risk difference retained for local delivery and population transfer. [hvip2026]
oV
0.8 non-overlapping fraction of combined violence prevention (judgment). 20% deducted for overlap between mediation and hospital pathways; also avoids separately adding Safe Passage injuries. [evaluation]
z
0.05 fatal share of prevented violent injuries (judgment). 5% fatality mix prior for prevented serious violent injuries; not a measured NCST outcome. [evaluation]
ui
0.2 utility burden of nonfatal violent injury (judgment). Physical and trauma burden of a new nonfatal injury; not a fiscal crime-cost conversion. [evaluation]
ri
0.5 annual nonfatal injury recovery rate (judgment). Recovery 0.5 annually; avoids permanent disability assumptions. [evaluation]
Ti
3 years nonfatal injury horizon (judgment). Finite three years. [evaluation]
ud
0.8 survivor utility after prevented violent death (judgment). 0.8 health-adjusted survival rather than full-quality life. [evaluation]
md
0.02 annual competing mortality hazard (judgment). 2% competing annual mortality; unique victims counted once. [evaluation]
Td
20 years violent-death survival horizon (judgment). Finite 20-year horizon. [evaluation]
T
265 reported trauma-program participants (observed). Return reports 265 participants alongside 202 clients described cumulatively; cannot interpret both as annual distinct totals. [return2024]
fT
0.5 fraction representing unique effective annual trauma episodes (judgment). 50% prior for annual unique completed clinical episodes, removing ambiguous reach and attendance duplication. [evaluation]
pT
0.15 incremental trauma responders per episode (judgment). 15% extra recovery beyond natural recovery and ordinary care; not observed locally. [evaluation]
uT
0.15 utility improvement per trauma responder (judgment). 0.15 utility gain among extra responders, not a validated scale conversion. [evaluation]
rT
0.5 annual trauma-effect decay (judgment). Effect decays at 0.5 annually. [evaluation]
TT
2 years trauma follow-up (judgment). Finite two-year trauma benefit; existing injuries only, distinct from prevented new injuries. [evaluation]
R
30 reported naloxone reversals (observed). 30 reported reversals in 2024; neither 30 deaths prevented nor 30 necessarily unique people. [return2024]
oR
0.7 unique-person fraction of reversals (judgment). 70% unique-person prior to prevent repeat-rescue lifetime double counting. [return2024] [naloxone] [heal]
tR
0.2 fraction without otherwise timely effective rescue (judgment). 20% would lack timely alternative rescue; 27 arrivals before EMS does not identify this parameter. [return2024] [naloxone] [heal]
deltaR
0.2 mortality risk reduction in that rescue subset (judgment). 20% absolute mortality difference within the otherwise untimely-rescue subset, not among all contacts. [return2024] [naloxone] [heal]
uR
0.65 utility among overdose survivors (judgment). 0.65 utility, reflecting morbidity in a high-risk rescued cohort. [evaluation]
mR
0.1 annual competing mortality hazard after rescue (judgment). 10% annual competing mortality includes subsequent fatal overdose and other causes. [return2024] [naloxone] [heal]
TR
10 years overdose survival horizon (judgment). Finite 10-year survival; no automatic lifetime credit or extra post-rescue SUD benefit. [evaluation]
a
0.5 NCST attributable service share within the delivery ecosystem (judgment). 50% recipient contribution within hospital, emergency and clinical partnerships; no credit for the whole local coalition. [current] [audit2024]
b
0.25 ordinary donor funding-response fraction (judgment). 25% marginal response to an ordinary gift; public contracts, reserve substitution and referral limits persist. [current] [audit2024]
g
0.98 NYC MSA fraction of priced health (judgment). 98% because modeled direct pathways serve Newark, allowing migration outside official 22-county MSA. National CBPSC benefits excluded. [current] [audit2024]
h
0.00 additional QALY harm before attribution/funding multipliers (judgment). Zero central; one additional QALY of harm in adverse scenario beyond increased violent injury. [evaluation]
d
0.03 annual discount rate (judgment). 3% annually; continuous-equivalent log(1+d). [evaluation]

Conditional multi-pathway health central: Cost: $6.4M; New York City health QALYs: 1.15; all-population health QALYs: 1.18. {"C":6443440,"M":119,"fM":0.6,"pM":0.03,"H":137,"fH":0.8,"r0":0.1,"OR":0.6,"l":0.5,"oV":0.8,"z":0.05,"ui":0.2,"ri":0.5,"Ti":3,"ud":0.8,"md":0.02,"Td":20,"T":265,"fT":0.5,"pT":0.15,"uT":0.15,"rT":0.5,"TT":2,"R":30,"oR":0.7,"tR":0.2,"deltaR":0.2,"uR":0.65,"mR":0.1,"TR":10,"a":0.5,"b":0.25,"g":0.98,"h":0,"d":0.03}

Low current reach and incremental benefit: Cost: $6.4M; New York City health QALYs: 0.02; all-population health QALYs: 0.02. {"C":6443440,"M":119,"fM":0.3,"pM":0.005,"H":137,"fH":0.5,"r0":0.1,"OR":0.94,"l":0.25,"oV":0.8,"z":0.05,"ui":0.2,"ri":0.5,"Ti":3,"ud":0.8,"md":0.02,"Td":20,"T":265,"fT":0.25,"pT":0.03,"uT":0.15,"rT":0.5,"TT":2,"R":30,"oR":0.7,"tR":0.05,"deltaR":0.1,"uR":0.65,"mR":0.1,"TR":10,"a":0.25,"b":0.1,"g":0.98,"h":0,"d":0.03}

Higher clinical reach and incremental benefit: Cost: $6.4M; New York City health QALYs: 11.12; all-population health QALYs: 11.35. {"C":6443440,"M":119,"fM":0.9,"pM":0.08,"H":137,"fH":1,"r0":0.1,"OR":0.38,"l":0.75,"oV":0.8,"z":0.05,"ui":0.2,"ri":0.5,"Ti":3,"ud":0.8,"md":0.02,"Td":20,"T":265,"fT":0.8,"pT":0.3,"uT":0.15,"rT":0.5,"TT":2,"R":30,"oR":0.7,"tR":0.4,"deltaR":0.3,"uR":0.65,"mR":0.1,"TR":10,"a":0.75,"b":0.5,"g":0.98,"h":0,"d":0.03}

No marginal funding response: Cost: $6.4M; New York City health QALYs: 0.00; all-population health QALYs: 0.00. {"C":6443440,"M":119,"fM":0.6,"pM":0.03,"H":137,"fH":0.8,"r0":0.1,"OR":0.6,"l":0.5,"oV":0.8,"z":0.05,"ui":0.2,"ri":0.5,"Ti":3,"ud":0.8,"md":0.02,"Td":20,"T":265,"fT":0.5,"pT":0.15,"uT":0.15,"rT":0.5,"TT":2,"R":30,"oR":0.7,"tR":0.2,"deltaR":0.2,"uR":0.65,"mR":0.1,"TR":10,"a":0.5,"b":0,"g":0.98,"h":0,"d":0.03}

Increased conflict and no clinical gains: Cost: $6.4M; New York City health QALYs: -0.31; all-population health QALYs: -0.32. {"C":6443440,"M":119,"fM":0.6,"pM":-0.02,"H":137,"fH":0.8,"r0":0.1,"OR":1.1,"l":1,"oV":0.8,"z":0.05,"ui":0.2,"ri":0.5,"Ti":3,"ud":0.8,"md":0.02,"Td":20,"T":265,"fT":0.5,"pT":0,"uT":0.15,"rT":0.5,"TT":2,"R":30,"oR":0.7,"tR":0,"deltaR":0.2,"uR":0.65,"mR":0.1,"TR":10,"a":0.5,"b":0.25,"g":0.98,"h":1,"d":0.03}

No additional overdose survival: Cost: $6.4M; New York City health QALYs: 0.78; all-population health QALYs: 0.79. {"C":6443440,"M":119,"fM":0.6,"pM":0.03,"H":137,"fH":0.8,"r0":0.1,"OR":0.6,"l":0.5,"oV":0.8,"z":0.05,"ui":0.2,"ri":0.5,"Ti":3,"ud":0.8,"md":0.02,"Td":20,"T":265,"fT":0.5,"pT":0.15,"uT":0.15,"rT":0.5,"TT":2,"R":30,"oR":0.7,"tR":0,"deltaR":0.2,"uR":0.65,"mR":0.1,"TR":10,"a":0.5,"b":0.25,"g":0.98,"h":0,"d":0.03}

No additional violent injury prevention: Cost: $6.4M; New York City health QALYs: 0.83; all-population health QALYs: 0.84. {"C":6443440,"M":119,"fM":0.6,"pM":0,"H":137,"fH":0.8,"r0":0.1,"OR":1,"l":0.5,"oV":0.8,"z":0.05,"ui":0.2,"ri":0.5,"Ti":3,"ud":0.8,"md":0.02,"Td":20,"T":265,"fT":0.5,"pT":0.15,"uT":0.15,"rT":0.5,"TT":2,"R":30,"oR":0.7,"tR":0.2,"deltaR":0.2,"uR":0.65,"mR":0.1,"TR":10,"a":0.5,"b":0.25,"g":0.98,"h":0,"d":0.03}

Unadjusted audited expense: Cost: $6.3M; New York City health QALYs: 1.15; all-population health QALYs: 1.18. {"C":6286421,"M":119,"fM":0.6,"pM":0.03,"H":137,"fH":0.8,"r0":0.1,"OR":0.6,"l":0.5,"oV":0.8,"z":0.05,"ui":0.2,"ri":0.5,"Ti":3,"ud":0.8,"md":0.02,"Td":20,"T":265,"fT":0.5,"pT":0.15,"uT":0.15,"rT":0.5,"TT":2,"R":30,"oR":0.7,"tR":0.2,"deltaR":0.2,"uR":0.65,"mR":0.1,"TR":10,"a":0.5,"b":0.25,"g":0.98,"h":0,"d":0.03}

Additional treatment and emergency resources: Cost: $6.6M; New York City health QALYs: 1.15; all-population health QALYs: 1.18. {"C":6607877.5,"M":119,"fM":0.6,"pM":0.03,"H":137,"fH":0.8,"r0":0.1,"OR":0.6,"l":0.5,"oV":0.8,"z":0.05,"ui":0.2,"ri":0.5,"Ti":3,"ud":0.8,"md":0.02,"Td":20,"T":265,"fT":0.5,"pT":0.15,"uT":0.15,"rT":0.5,"TT":2,"R":30,"oR":0.7,"tR":0.2,"deltaR":0.2,"uR":0.65,"mR":0.1,"TR":10,"a":0.5,"b":0.25,"g":0.98,"h":0,"d":0.03}

25% additional resource costs: Cost: $8.1M; New York City health QALYs: 1.15; all-population health QALYs: 1.18. {"C":8054300,"M":119,"fM":0.6,"pM":0.03,"H":137,"fH":0.8,"r0":0.1,"OR":0.6,"l":0.5,"oV":0.8,"z":0.05,"ui":0.2,"ri":0.5,"Ti":3,"ud":0.8,"md":0.02,"Td":20,"T":265,"fT":0.5,"pT":0.15,"uT":0.15,"rT":0.5,"TT":2,"R":30,"oR":0.7,"tR":0.2,"deltaR":0.2,"uR":0.65,"mR":0.1,"TR":10,"a":0.5,"b":0.25,"g":0.98,"h":0,"d":0.03}

Combined resources unknown; clinical reference retained: Cost: $6.4M; New York City health QALYs: 1.15; all-population health QALYs: 1.18. Original clinical model and full annual recipient resource scope retained; signed household resources unknown, not zero.

Counterfactual: Emergency medical response, ordinary hospital/mental-health care, funded local safety programs and natural recovery continue. External HVIP evidence is attenuated before assigning NCST’s contribution; overdose timely-rescue substitution is modeled explicitly. Funding response b applies once, not again per program.

Attribution: No causal credit for city crime trends, public meeting attendance or historical program existence. The priced pathways span the central clinical mission, while Safe Passage’s broader safety, community organizing, housing and national learning effects are explicitly unpriced. a is contribution within delivered care, not another donor multiplier. Existing-trauma utility gains must be additional on person-time alive in both arms and exclude utility already included in newly added survival years. The overdose unique-person adjustment must also remove repeat rescues and any survivor already credited a prevented violent death. These are modeling assumptions, not observed linked-person exclusions.

Clinical conversion, native event risks, current annual reach, overlap and funding response are judgments. The range is not a statistical interval; pooled OR confidence limits are only ingredients in broader scenarios. Negative effects and zero are possible.

Sensitivity

  • The range varies current-effective reach rather than treating repeated historical counts as confirmed annual capacity.
  • The no-overdose and no-violence scenarios expose dependence on each material clinical channel.
  • Survival is finite and discounted with competing mortality; no rescued person receives multiple lives.
  • The adverse case permits net escalation, worse reinjury and separate harm.
  • The external-cost case adds $5,000 per donor-attributable hospital, trauma and unique rescue episode; resource and audited-cost alternatives are separate.
  • Attribution and funding response each apply once; zero funding elasticity eliminates all marginal health.

Unresolved inputs

  • Reconciled current annual unique clients, mediations, repeat responses and cross-program overlap.
  • Matched or randomized injury and trauma outcomes, all-referral follow-up and a defensible untreated reinjury risk.
  • Unique overdose patients, arrival-time counterfactual, clinical severity and later mortality.
  • Current contract renewals, funding restrictions and the actual capacity opened or protected by an ordinary gift.
  • External treatment resources, induced emergency costs and incremental school/community spillovers.
  • Post-2024 audited finances and sustained financial-control implementation.
  • Deduplicated funding-responsive households, actual assistance paid and retained compensation, displaced private payments versus free alternatives, household net baseline, full access/work burdens, finite timing and payer incidence.

5. Funding and previous grants

The ordinary NCST donation route must not be confused with an optional CBPS Collective designation. The 2024 audit reports $1,288,345 due to CBPSC, remitted in 2025; this liability is not newly purchased NCST service. The FY2024 return reports $3,593,335 government grants and $688,476 Safe Passage revenue; the audit presents program-service revenue as $688,475, a one-dollar filing difference not used to alter cost; $1,487,559 of $3,681,801 net assets was donor restricted. The 2023 audit reported misappropriation connected to weak bank-reconciliation review. The latest audit reports these controls corrected and no new significant financial-reporting deficiencies, while retaining a repeated late-filing finding. The model does not assume a current unfunded gap: only 25% of proportionate delivery is attributed to marginal funding in the central case, and a zero-response case remains.

Annual expenses

Organization-level spending, including programs, administration and fundraising. The research list averages three comparable, consecutive full fiscal years when available.

  • FY 2022: $6.4M; NCST including CBPSC fiscal-sponsorship perimeter, 12-month period, Accrual gross audited recipient expense including recognized donated services; annual historical figures retain allowance/recovery accounting. Source
  • FY 2023: $8.1M; Newark Community Street Team, Inc., 12-month period, Accrual gross audited recipient expense including recognized donated services; annual historical figures retain allowance/recovery accounting. Source
  • FY 2024: $6.3M; Newark Community Street Team, Inc., 12-month period, Accrual gross audited recipient expense including recognized donated services; annual historical figures retain allowance/recovery accounting. Source

6. Sources

  1. FY2024 original Form 990. NCST / IRS. Published: not stated; retrieved: 2026-09-14.
  2. FY2024 Schedule D donated-service reconciliation. NCST / IRS. Published: not stated; retrieved: 2026-09-14.
  3. FY2024 original audited financial statements and findings. Brunhofer & Balise, LLP / NCST. Published: not stated; retrieved: 2026-09-14.
  4. FY2023 original Form 990. NCST / IRS. Published: not stated; retrieved: 2026-09-14.
  5. FY2023 original Schedule D reconciliation. NCST / IRS. Published: not stated; retrieved: 2026-09-14.
  6. FY2023 original audit and corrective actions. Brunhofer & Balise, LLP / NCST. Published: not stated; retrieved: 2026-09-14.
  7. FY2022 original Form 990. NCST / IRS. Published: not stated; retrieved: 2026-09-14.
  8. FY2022 original Schedule D reconciliation. NCST / IRS. Published: not stated; retrieved: 2026-09-14.
  9. NCST Evaluation and Proof of Concept, November 2025. Leap et al. / UCLA evaluation commissioned by CBPSC and funded by Ford Foundation. Published: not stated; retrieved: 2026-09-14.
  10. Current programs. Newark Community Street Team. Published: not stated; retrieved: 2026-10-08.
  11. Ordinary donation route. Newark Community Street Team. Published: not stated; retrieved: 2026-09-14.
  12. Hospital violence intervention systematic review and guideline, 2026 update. Jawa et al. / Journal of Trauma and Acute Care Surgery. Published: 2026-08-18; retrieved: 2026-09-14.
  13. Earlier review finding insufficient adult HVIP evidence. Affinati et al. / Trauma Surgery & Acute Care Open. Published: 2016-09-28; retrieved: 2026-09-14.
  14. Overdose education and naloxone distribution interrupted time-series study. Walley et al. / BMJ. Published: not stated; retrieved: 2026-09-14.
  15. Community-based cluster-randomized trial to reduce opioid overdose deaths. HEALing Communities Study / New England Journal of Medicine. Published: not stated; retrieved: 2026-09-14.